title: [Erectile dysfunction and renal chronic insufficiency: etiology and management].
abstract: Erectile dysfunction (ED) has a higher incidence in patients treated for chronic renal insufficiency or in patients who underwent kidney transplanation as it concerns more than 50% of them. Its severity is directly linked with the seriousness of the renal disease. ED is responsible of a deterioration of the quality of life. ED's physiopathology is complex and multifactorial, involving a combination of classical risk factors (endothelial dysfunction), specific factors (e.g., chronic hyperuremia and co-morbidities) and psychological factors. Management of ED must take into account both sides of the disease in order to propose appropriate treatment; i.e, psychological concerns and organic matters. Although literature remains poor in this area, phosphodiesterase-5 inhibitors are increasingly used for these patients as they are safe and efficient most of the time. Pharmacokinetics of phosphodiesterase-5 inhibitors can be disturbed by the simultaneous use of immunosuppressor. As a second line, intra-cavernous injections remain a gold-standard treatment. In case of failure, penile prosthesis can even be considered in case of renal chronic insufficiency and in transplanted patients.
authors.affiliation: Service d'urologie, hôpital Tenon, AP-HP, faculté de médecine Pierre-et-Marie-Curie, université Paris-VI, groupe hospitalo-universitaire Est, 4, rue de la Chine, 75020 Paris, France.
authors.forename: V
authors.initials: V
authors.lastname: Phé
authors.forename: M
authors.initials: M
authors.lastname: Roupret
authors.forename: K
authors.initials: K
authors.lastname: Ferhi
authors.forename: B
authors.initials: B
authors.lastname: Barrou
authors.forename: O
authors.initials: O
authors.lastname: Cussenot
authors.forename: O
authors.initials: O
authors.lastname: Traxer
authors.forename: F
authors.initials: F
authors.lastname: Haab
authors.forename: S
authors.initials: S
authors.lastname: Beley
mesh_terms: D007172:Erectile Dysfunction / Q000188:drug therapy / Q000209:etiology* / Q000628:therapy*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D058986:Phosphodiesterase 5 Inhibitors; D011795:Surveys and Questionnaires
chemical_list: D058986:Phosphodiesterase 5 Inhibitors